Fierce Pharma
FEBRUARY 5, 2024
Less than two months after the FDA approved the combination treatment of Astellas and Pfizer’s Padcev and Merck’s Keytruda in first-line bladder cancer, the Japanese company has
MedCity News
FEBRUARY 5, 2024
After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions, and they will help the company meet projected demand for these products in years to come.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 5, 2024
After leading Novartis and Roche through pivotal years in 2023, the CEOs of the Swiss drug giants each netted multimillion-dollar compensation packages. | After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023.
MedCity News
FEBRUARY 5, 2024
This year, industry experts think that some digital health startups will have to confront their challenges more head-on than they did in 2023. Some companies may need to do things like fundraise at a lower valuation, explore opportunities for an acquisition or exit or, in some cases, consider the possibility of shutting down operations.
Fierce Pharma
FEBRUARY 5, 2024
If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. | If a new package of pivotal data satisfies the FDA, GSK could have another run at the U.S. multiple myeloma market with its previously withdrawn BMCA-targeted antibody-drug conjugate, Blenrep.
MedCity News
FEBRUARY 5, 2024
The only way to effectively scale care coordination to meet the needs of digital consumers is through technology, combined with empowered staff and transformed processes.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 5, 2024
Virtual nursing, a concept that marries the strengths of traditional nursing models – primary nursing and team nursing – is emerging as a promising solution to address the challenges faced by healthcare organizations.
Fierce Pharma
FEBRUARY 5, 2024
Late last month, Novo Holdings’ CEO Kasim Kutay hinted that the fund manager was eyeing buyouts as an outlet for its trove of Wegovy cash. Now, a major deal has materialized. | Late last month, Novo Holdings’ CEO Kasim Kutay hinted that the fund manager was eyeing buyouts as an outlet for its trove of Wegovy cash. Now, a major deal has materialized.
MedCity News
FEBRUARY 5, 2024
Employers have been making major investments in healthcare for their employees. Yet, many disparities still exist, particularly when it comes to access and outcomes, according to a recent report from Morgan Health.
Fierce Pharma
FEBRUARY 5, 2024
After Novartis reportedly backed out of late-stage talks to acquire Cytoki | The company has a leading bid for the cancer drug maker over Incyte, Reuters reports, citing two people familiar with the matter.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
FEBRUARY 5, 2024
Based on the risk profiles of orthopaedic operations, a shoulder replacement is actually safer than that of a hip or knee and therefore an ideal candidate for the ambulatory surgical center environment.
Fierce Pharma
FEBRUARY 5, 2024
By Matthew Cotter, PhD, Vice President, Global Medical Affairs, Prostate Cancer, Pfizer Oncology Sponsored by Pfizer Inc. | Ongoing scientific research is needed to better understand prostate cancer and identify treatment options to help address unmet needs of patients.
European Pharmaceutical Review
FEBRUARY 5, 2024
Novo Nordisk is set to acquire three fill-finish manufacturing sites from Novo Holdings A/S (Novo Holdings) for $11 billion. This agreement is part of a transaction in which Novo Holdings agreed to acquire the contract development and manufacturing organisation (CDMO) Catalent. The three manufacturing sites in Anagni in Italy, Brussels in Belgium and in Bloomington, Indiana in the US, specialise in the sterile filling of drugs.
pharmaphorum
FEBRUARY 5, 2024
A bladder cancer study prompts Astellas to lift peak sales prediction for Padcev, although its menopause therapy Veozah isn’t ramping up as hoped.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
FEBRUARY 5, 2024
Several recent developments signal increased support for psychological assessments and treatments.
pharmaphorum
FEBRUARY 5, 2024
Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.
MedCity News
FEBRUARY 5, 2024
Health aid from the private US healthcare community to Ukraine is stalling. To re-engage and do more we should take a bottom-up and people-centric approach to aid and focus on long term needs.
PharmaTimes
FEBRUARY 5, 2024
The aggressive brain cancer is responsible for over 3,000 cases in the UK every year
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
FEBRUARY 5, 2024
4D Molecular Therapeutics' 4D-150 gene therapy for wet AMD has shown efficacy and a reduced need for eye injections with current therapy Eylea in a phase 2 trial.
Pharmaceutical Technology
FEBRUARY 5, 2024
Regeneron Pharmaceuticals' application for linvoseltamab has received acceptance from the EMA for review to treat multiple myeloma.
pharmaphorum
FEBRUARY 5, 2024
The first patient has been treated in a phase 1/2 trial of a Moderna cancer vaccine designed to generate antibodies against immune checkpoints PD-L1 and IDO1
European Pharmaceutical Review
FEBRUARY 5, 2024
Incentivising small molecule drug innovation According to the Biotechnology Innovation Organization (BIO), the bipartisan Ensuring Pathways to Innovative Cures ( EPIC Act ) passed last week in the US, is a “critical” step for incentivising small molecule drug innovation. Representative Congressman Dr Greg Murphy, alongside Don Davis and Brett Guthrie, introduced the US legislation to fix the “pill penalty”, BIO confirmed.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
FEBRUARY 5, 2024
Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes and obesity drugs. The deal includes $11 billion upfront to buy the fill-finish sites that Novo Nordisk said will enable “an expansion of the manufacturing capacity at scale and speed while providing future optionality and flexibility for Novo Nordisk’s existing supply network.
PharmaTimes
FEBRUARY 5, 2024
The neurodegenerative condition currently affects over 944,000 people in the UK
pharmaphorum
FEBRUARY 5, 2024
The 38th PM Society Awards will take place on Friday 15th March in London, with Twist Health as the headline sponsor. It is the longest running and largest awards event in the pharma marketing and healthcare agency calendar. To view all the finalist agencies and clients, please visit the PM Society’s website.
Pharmaceutical Technology
FEBRUARY 5, 2024
Tozorakimab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD).
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Commerce
FEBRUARY 5, 2024
An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.
Pharmaceutical Technology
FEBRUARY 5, 2024
V-116 is a conjugate vaccine commercialized by Merck, with a leading Pre-Registration program in Streptococcal Pneumonia.
Spotio
FEBRUARY 5, 2024
Tom Brady had Bill Belichick. Michael Jordan had Phil Jackson. And the University of Connecticut women’s basketball team has had Geno Auriemma since 1985. What do these three people have in common? They’re all great coaches who elevate their players to new heights—and have plenty of championships to prove their worth. It doesn’t matter if you’re working with top-level athletes or sales reps, coaching matters.
Referral MD
FEBRUARY 5, 2024
In this episode of the Healthcare Leadership Podcast , host Jennifer Thompson engages in a dynamic discussion with Matthew Davis, Director of Channel Partnerships at Press Ganey. Together, they explore the latest 2021 Consumer Experience Trends in Healthcare report insights. The conversation sheds light on the evolving patient habits and the importance of maintaining a strong digital presence for healthcare practices.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
285 
Let's personalize your content